학술논문

Novel Biomarkers Do Not Correlate with Severity of Vascular Stiffness in CKD Patients with Severe Co-Morbid Disease.
Document Type
Article
Source
Nephron Clinical Practice. Oct2011, Vol. 119 Issue 3, pc261-c268. 8p. 4 Charts, 3 Graphs.
Subject
*BIOMARKERS
*PERIPHERAL vascular diseases
*KIDNEY diseases
*CONGESTIVE heart failure
*PEPTIDES
*CHOLESTEROL
*ALPHA fetoproteins
*INTERLEUKINS
Language
ISSN
1660-2110
Abstract
Background/Aims: Novel biomarkers may help explain the pathobiology of vascular disease in chronic kidney disease, and thus set the stage for identification of therapeutic targets, potential reversibility, and improved outcomes in this population. Methods: 124 subjects with GFR <60 ml/min or on renal replacement therapy underwent measurement of inflammatory, vascular and cardiac biomarkers as well as aortic pulse wave velocity (PWV) testing. A subset of patients (n = 60) had repeat PWV measured at 6 months. Results: Thirty-four percent of the patients were diabetic, and 50% had a history of cardiovascular disease or congestive heart failure. Median PWV was 9.8 (IQR 8.3-12.7) m/s. No significant correlations between the measured biomarkers and baseline PWV was observed. An increase in PWV (>1.5 m/s) over 6 months was observed in those subjects with diabetes, a higher brain natriuretic peptide level, lower cholesterol and lower phosphate level. Age (HR 1.086, p = 0.0028), fetuin (0.024, p = 0.0448), and interleukin-10 (top tertile HR 4.720, p = 0.0359) were associated with mortality. Conclusions: In this cohort of patients with chronic kidney disease and diabetes and/or heart disease, we were unable to demonstrate that select biomarkers can inform processes leading to vascular disease. Biomarkers do appear to have utility in predicting future events in this population. Copyright © 2011 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]